96 Tests PN: B113331

Components:

45x Ab-conjugated beads (S4P6 - human sCEACAM-1 Ab-bead). PN: B113331A. One vial containing 100 µL of anti-human sCEACAM-1 conjugated to AimPlex Bead S4P6.

25x Biotin-detection (human sCEACAM-1 Biotin-dAb). PN: B113331B. One vial containing 100 µL of biotinylated anti-human sCEACAM-1.

Lyophilized Standard Mix-Human Group 9 Panel B, 9-Plex. PN: HG9009B. One vial containing lyophilized recombinant human sCEACAM-1, sALCAM, sSLAMF4, sHVEM, sB7-DC, sB7-H1, sEpCAM, sBLAME and sEPOR. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Human CEACAM-1/sCD66a. Can be multiplexed with other analytes in Human Group 9.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 9: Negligible

  • Sample volume: 15 µL/test

Description:

CEACAM1 (Carcinoembryonic antigen-related cell adhesion molecule 1) also known as CD66a (Cluster of Differentiation 66a), is a human glycoprotein. The protein was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, it was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses Diseases associated with CEACAM1 include gonorrhea and adenomatoid tumor.

References:

  1. Hoek KS, Schlegel NC, Eichhoff OM; et al. (2008). "Novel MITF targets identified using a two-step DNA microarray strategy". Pigment Cell Melanoma Res. 21 (6): 665–76. doi:10.1111/j.1755-148X.2008.00505.x. PMID 19067971.

  2. Huber, M; Izzi L; Grondin P; Houde C; Kunath T; Veillette A; Beauchemin N (Jan 1999). "The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells". J. Biol. Chem. (UNITED STATES) 274 (1): 335–44. doi:10.1074/jbc.274.1.335. ISSN 0021-9258. PMID 9867848.

  3. Kirshner, Julia; Schumann Detlef; Shively John E (Dec 2003). "CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis". J. Biol. Chem. (United States) 278 (50): 50338–45. doi:10.1074/jbc.M309115200. ISSN 0021-9258. PMID 14522961.